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ABSTRACT 
Objective: Objective evaluation of disease activity is challenging in patients with juvenile 
dermatomyositis (JDM) due to lack of biomarkers, but crucial to avoid both under- and 
overtreatment. Recently, we identified two proteins that highly correlate with JDM disease 
activity: galectin-9 and CXCL10. Here, we validate galectin-9 and CXCL10 as biomarkers 
for disease activity, assess disease-specificity and investigate their potency to predict flares.  
 
Methods: Galectin-9 and CXCL10 were measured in serum samples of 125 unique JDM 
patients in three international cross-sectional cohorts and a local longitudinal cohort, by 
multiplex immunoassay. Disease-specificity was examined in 50 adults with 
(dermato)myositis and 61 patients with other systemic autoimmune diseases.  
 
Results: Galectin-9 and CXCL10 outperformed the currently used marker creatine kinase 
(CK) to distinguish between JDM patients with active disease and remission, both cross-
sectionally and longitudinally (area ROC curve: 0.86-0.90 for galectin-9 and CXCL10, 0.66-
0.68 for CK). The sensitivity and specificity were 0.84 and 0.92 for galectin-9, and 0.87 and 
1.00 for CXCL10. In 10 prospectively followed patients with a flare, continuously elevated 
or rising biomarker levels suggested an imminent flare up to several months before 
symptoms, even in absence of elevated CK. Galectin-9 and CXCL10 distinguished between 
active disease and remission in adults with (dermato)myositis and were suited for 
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Conclusions: Galectin-9 and CXCL10 were validated as sensitive and reliable biomarkers 
for disease activity in (J)DM. Implementation of these biomarkers into clinical practice, as 




Juvenile dermatomyositis (JDM) is a rare, chronic systemic immune-mediated disease with a 
high disease burden. JDM is characterized by inflammation of skeletal muscles and skin, 
leading to muscle weakness and a pathognomonic skin rash. Vital organs such as the lung 
and heart can also be involved. Although the pathogenesis is still largely unknown, 
environmental and genetic factors may predispose to the disease. (1–5) The autoimmune 
process is characterized by a type I interferon signature and by infiltration of immune cells 
such as plasmacytoid dendritic cells, B cells, CD4
+
 T cells and macrophages into skin and 
muscle tissue. (6–9)  
 
Children with JDM are at risk of both under- and overtreatment due to lack of reliable 
biomarkers for disease activity. Current treatment guidelines recommend immunosuppression 
for at least two years, tapering steroids over the first year and withdrawing treatment if a 
patients has been off steroids and in remission on methotrexate (or alternative DMARD) for a 
minimum of 1 year. (10–12) However, for some patients this standardized regimen may not 
be optimal. Approximately 50% of patients do not respond to initial treatment or present with 
disease flares during follow-up, resulting in additional tissue damage and impaired physical 
recovery. (13–15) In the other half of patients some could likely benefit from shorter 
treatment duration, taking into account that overtreatment with steroids can result in serious 
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To determine the rate of medication tapering and to avoid both under- and overtreatment, 
objective measurement of disease activity and subclinical inflammation is crucial. However, 
validated and reliable biomarkers for disease activity are lacking. (19) Disease activity is 
currently assessed by a combination of muscle enzyme testing and clinical evaluation; 
(10,20–22) the latter depends on the experience of the health care professionals and the 
patient’s collaboration. Muscle enzymes, including serum creatine kinase (CK) activity, have 
been shown to correlate only moderately with disease activity in JDM and the erythrocyte 
sedimentation rate and C-reactive protein are rarely elevated in patients with JDM. (23–25) 
Lack of objective tools or biomarkers to monitor response to therapy also hampers clinical 
trial design. Thus, there is an unmet need for an objective and reliable measure for disease 
activity.  
 
Recently, we have demonstrated that three proteins, galectin-9, CXCL10 and TNFRII, 
distinguish between active disease and remission in a cross-sectional cohort of patients with 
JDM, with galectin-9 and CXCL10 being the most discriminative markers. (26,27) CXCL10 
and galectin-9 can be produced by a variety of cells, both immune and non-immune, upon 
stimulation with interferons. (28,29) CXCL10 has been reported as a biomarker in several 
human autoimmune diseases including myositis, (29–33) whereas galectin-9 has been mainly 
investigated as a biomarker in cancer and viral infections. (28,34) Reports on the role of 
galectin-9 in autoimmunity are conflicting, suggesting either an attenuating or aggravating 
effect on autoimmune manifestations in experimental models. (35,36) Its role in human 
autoimmune diseases has yet to be elucidated. Here, we aim to validate galectin-9 and 
CXCL10 as biomarkers for active disease in JDM, examine disease-specificity in adult 
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their potency to predict flares and test the applicability of the biomarkers in minimally-
invasive dried blood spots, to aid broad implementation into clinical practice.  
 
PATIENTS AND METHODS 
Cohorts 
125 unique patients with JDM from three independent cross-sectional international cohorts 
and one Dutch prospective cohort participated, which were included between May 2001 and 
May 2017. Two large cohorts from Utrecht and London were used for validation of the 
biomarkers; a third smaller cohort from Singapore was used to assess international 
generalizability. An overview of all cohorts is shown in table 1. The internal validation 
cohort (IVC) from Utrecht does not overlap with the previously reported discovery cohort. 
(26) For specific questions including disease specificity, longitudinal follow-up and 
measurements in dried blood spots, a combination of samples from the IVC and new patients 
was used.  
 
Participants 
Patients with JDM were included if they met the Bohan and Peter criteria for definite or 
probable JDM. (37,38) The childhood myositis scale (CMAS; 0-52), manual muscle testing 
of 8 muscle groups (MMT-8; 0-80) and physician’s global assessment (PGA; 0-10) were 
recorded as clinical measures of muscle and global disease activity. Cutaneous assessment 
tool scores measuring skin disease (CAT; 0-116) were additionally recorded in Dutch and 
Singaporean patients. Disease remission was defined according to the updated criteria for 
clinically inactive disease, and, in case of missing data by clinical description, as indicated in 
the table legends. (39) All other patients were considered active. Flares were defined as the 
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to start tapering steroids, worsening of at least one out of three clinical scores (CMAS, PGA, 
CAT) with two or more points and the decision to start new immunosuppressive treatment or 
increase the current dose.  
 
Adult patients with dermatomyositis (DM) and non-specific myositis (NSM), were classified 
according to the ENMC criteria. (40) Myositis was confirmed by biopsy unless typical skin 
manifestations of dermatomyositis were present. Patients with cancer-associated myositis 
were excluded. Disease activity was determined by combined evaluation of muscle strength 
with the medical research council (MRC) scale, skin symptoms and muscle enzymes. To 
determine the disease specificity of the biomarkers, different disease controls were added in 
the study: Paediatric and adult patients with systemic lupus erythematosus (SLE), paediatric 
patients with localized scleroderma, adult patients with eosinophilic fasciitis (EF) and 
paediatric and adult patients with hereditary proximal spinal muscular atrophy (SMA). All 
controls had either systemic inflammation, inflammation of skin or muscles or had a non-
inflammatory neuromuscular disorder. Patients with SLE fulfilled the ACR classification 
criteria for SLE. (41) Active disease was defined as a SLEDAI score ≥ 4 out of 105. (42) 
Patients with LoS were diagnosed based on the typical clinical picture. Active disease was 
defined as a modified LoS Skin Severity Index (mLoSSi) ≥ 5 out of 162. (43) Patients with 
EF were diagnosed based on the clinical picture and histopathological evaluation of skin 
biopsies containing the fascia. As the mLoSSi may stay high in these patients due to 
extensive irreversible sclerosis despite improved inflammatory symptoms, active disease was 
defined as a PGA for activity ≥ 5 out of 100. (43) Patients with hereditary proximal SMA, a 
progressive, non-inflammatory neuromuscular disorder, were diagnosed by genetic 
confirmation of a homozygous loss of function of the survival motor neuron 1 gene and 
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Ethical approval 
This study was approved by the institutional ethics committees of the involved centres (UMC 
Utrecht (METC 15-191 and 12-466), United Kingdom (MREC1/3/22), CHUV Lausanne, 
CHU Strasbourg, SingHealth centralized IRB, AMC Amsterdam) and conducted according to 
the Declaration of Helsinki. Written informed consent was obtained prior to inclusion in the 
study, from patients and from parents or legal representatives when the patient was less than 
12 years old. 
 
Patient material  
Blood was collected in serum tubes, according to the local study protocol (all participating 
centers). At the UMC Utrecht, sodium-heparin tubes were collected in addition to serum. All 
samples were spun down and aliquoted within four hours after collection and subsequently 
stored at -80°C until analysis. 
 
Dried blood spots 
Dried blood spots (DBS) were made by application of 50 µL sodium-heparin full blood to 
each spot on Whatman® 903 filter paper within four hours after blood was drawn. Spotted 
filter papers were dried for two days at room temperature to mimic mail delivery times and 
subsequently stored with desiccant in individual air tight polyethylene bags at -80°C under 
constant monitoring of humidity levels until analysis. Two circles of 3.0 mm in diameter 
(containing approximately 3 µl of whole blood each) were punched from the central part of 
one spot and eluted in 100 µL buffer (PBS containing 5 mL/L Tween-20, 10 g/L bovine 
serum albumin and complete protease inhibitor cocktail with EDTA (Roche, one tablet per 25 
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microshaker (600 rpm) and were spun down at 2100g for 2 minutes. The analysis was 
performed on the obtained eluate.  
 
Biomarker analysis 
Galectin-9 and CXCL10 were measured in 50 μL of serum, plasma or eluate by multiplex 
technology (xMAP; Luminex). CXCL10 was measured in undiluted material. Galectin-9 was 
measured in 10x diluted plasma or serum, except in the serum/plasma samples paired with 
DBS (here it was measured undiluted from eluate and serum/plasma). The multiplex 
immunoassay was performed as described previously. (45) Heterophilic immunoglobulins 
were pre-absorbed from all samples with HeteroBlock (Omega Biologicals). Acquisition was 
performed with a Bio-Rad FlexMAP3D in combination with xPONENT software version 4.2 
(Luminex). Data analysis was performed with Bioplex Manager 6.1.1 (Bio-Rad). Between 
measurement of the internal and external validation cohorts in 2015, the recombinant protein 
for galectin-9 was replaced, which affected the standard curve. Therefore, absolute values 
between these cohorts may not be comparable. Since 2015, the inter-luminex variability has 
been negligible. (46) All biomarker analyses were performed at the UMC Utrecht, thereby 
minimizing inter-centre variation. Treating physicians were blinded for biomarker levels and 
technicians performing the multiplex assay were blinded for clinical data. 
 
Statistical analysis 
Basic descriptive statistics were used to describe the patient population. Statistical analyses 
were performed using either GraphPad Prism 7.0 or SPSS Statistics 21 (IBM). Correlations 
were assessed by Spearman rank correlation. For comparisons between two groups, the 
Mann-Whitney U test (unpaired analysis) or the Wilcoxon matched-pairs signed rank test 
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variants of ANOVA with post hoc correction for multiple testing were used (Dunn’s post hoc 
test for Kruskall-Wallis and Šídák’s or Tukey’s post hoc test for 2-Way ANOVA, as 
indicated in the figure legends). Multiplicity adjusted P values less than 0.05 were considered 
statistically significant. To assess diagnostic accuracy, the area under the curve (AUC) in 
receiver operating characteristics (ROC) curves were constructed. Cutoff values for galectin-
9 and CXCL10 were determined based on the maximal Youden’s index with a sensitivity of 
at least 80%. 
 
RESULTS 
Cross-sectional validation of galectin-9 and CXCL10 
To validate the biomarker potential of galectin-9 and CXCL10, we measured the proteins in 
JDM patient samples from two independent validation cohorts: an external cohort (EVC) 
from London and an internal cohort (IVC) from Utrecht. The clinical characteristics of these 
cohorts are shown in supplementary table 1 and 2. As observed in the previously reported 
discovery cohort, (26) galectin-9 and CXCL10 levels were significantly higher in patients 
with active disease than in patients in remission (p<0.0001; supplementary figure 1A and B). 
The levels were highest at diagnosis before treatment, decreased steadily under treatment and 
were comparably low in remission with or without medication (figure 1A and B). The wide 
range of biomarker levels in the active group under treatment (“AM”) corresponds with a 
wide range of clinical disease activity within this group (CMAS range 3-44 in EVC, 10-52 in 
IVC; PGA range 2-8 in EVC, 1-9 in IVC). Both galectin-9 and CXCL10 were able to 
differentiate between patients with active disease on medication and patients in remission on 
medication, which is clinically important to assess response to treatment (“AM” versus 
“RM”; figure 1A and B). Paired analysis within individual patients comparing active disease 










© 2019 The Authors Arthritis & Rheumatology published by Wiley Periodicals, Inc. on 
behalf of American College of Rheumatology 
high discriminative power of both proteins (p=0.0078 in EVC and p=0.0002 in IVC; figure 
1C and D). 
 
To further assess the discriminative power of galectin-9 and CXCL10 for active disease and 
remission, we examined the AUC in ROC curves in the two separate cohorts. Comparing 
active disease and remission regardless of treatment status, galectin-9 and CXCL10 had an 
AUC of 0.894/0.863 and 0.877/0.902 (EVC/IVC), respectively (figure 1E and F; 
supplementary table 3). To take into account the effect of treatment, we also assessed the 
AUC of active disease versus remission in patients on medication. During treatment, 
galectin-9 and CXCL10 had an AUC of 0.844/0.776 and 0.860/0.840 (EVC/IVC), 
respectively (supplementary figure 1C and D; supplementary table 3). Moreover, galectin-9 
and CXCL10 performed better than the current standard laboratory marker CK in both 
cohorts (AUC of CK: 0.682/0.662 in EVC/IVC).  
 
To calculate the optimal cut-off value for distinguishing active disease and remission, we 
analysed the ROC curves of the internal validation cohort, as this cohort was measured 
according to the most recently optimized and standardized protocol of the multiplex 
immunoassay. (46) Based on the coordinates of this ROC curve we determined cut-off values 
for galectin-9 (19396 pg/mL) and CXCL10 (805 pg/mL) with a high sensitivity (0.84 for 
galectin-9 and 0.87 for CXCL10) and high negative predictive value (0.83 for galectin-9 and 
0.87 for CXCL10) for active disease, to ensure a low risk of ongoing inflammation in case of 
a test result below the cut-off (table 2). The specificity and positive predictive value were 
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Consistent with the previously reported discovery cohort, (26) galectin-9 and CXCL10 
correlated strongly with three clinical scores for global or muscle disease activity: PGA, 
CMAS and MMT-8. The correlation coefficients of both biomarkers, between 0.67 and 0.81 
(p<0.0001), were notably higher than those of CK (rs=0.32-0.51, p<0.01; figure 1G and H; 
supplementary figure 1E, F and G). In conclusion, we have validated galectin-9 and CXCL10 
in two independent validation cohorts as strong biomarkers for disease activity, which 
outperform the currently used laboratory marker CK.  
 
To assess the international generalizability of galectin-9 and CXCL10, we tested the 
biomarkers in a small JDM cohort from a different geographic region (i.e. Singapore). 
Observations in this cohort confirmed the discriminative potential of galectin-9 and CXCL10 
between active disease and remission, and levels were comparable to the IVC (p=0.0006 for 
galectin-9 and p=0.0025 for CXCL10; “JDM Sing” and “JDM NL”; figure 2A and B).  
 
Disease specificity of galectin-9 and CXCL10 
Next, we investigated the disease specificity of galectin-9 and CXCL10 and explored their 
applicability as biomarkers in adult patients with (dermato)myositis and patients with other 
systemic autoimmune diseases. The biomarkers were first measured in a cohort of adult 
patients with dermatomyositis (n=36), non-specific myositis (n=14), eosinophilic fasciitis 
(n=18) as well as 43 control patients with spinal muscular atrophy, a genetic neuromuscular 
disorder without systemic inflammation, and 22 healthy controls (supplementary table 4). 
Both galectin-9 and CXCL10 were elevated in adult patients with active DM (p<0.0001), 
NSM (p<0.0003) and EF (p<0.05) compared to healthy controls. Both biomarkers 
distinguished between active disease and remission in DM (p=0.0126 and p<0.0001); 
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figure 2A and B). As expected, the biomarkers were not elevated in SMA. A second cohort 
consisted of paediatric and adult patients with two other systemic immune-mediated diseases: 
localized scleroderma (n=15) and systemic lupus erythematosus (n=36) (supplementary table 
5). In LoS and SLE the two biomarkers did not distinguish significantly between active 
disease and remission, but galectin-9 levels in SLE were elevated compared to healthy 
controls (p=0.0105; figure 2C and D). In conclusion, galectin-9 and CXCL10 are applicable 
as biomarkers for disease activity in both paediatric and adult patients with myositis.  
 
Prospective analysis and flare prediction 
Next, to determine the prognostic value of galectin-9 and CXCL10 during clinical follow-up 
of JDM patients, we measured the biomarkers in a prospective cohort of 28 patients, with a 
median follow-up time of 2.8 years per patient (supplementary table 6). First, we established 
the biomarker dynamics after diagnosis in 15 patients who reached sustained remission 
within the first months of treatment and did not have a flare later. The biomarker levels 
quickly declined after start of treatment, reached levels below the previously determined cut-
off within several months, and remained low in remission (“No flare”; figure 3A and B). The 
biomarker dynamics of patients with a flare after the first year (“Flare >12 months”; n=7) 
were similar to those of patients without flares (figure 3C and D). However, patients 
suffering from a disease flare in the first year after start of treatment (“Flare <12 months”; 
n=6) had significantly higher biomarker levels at diagnosis than patients with later flares 
(p=0.0254 for galectin-9 and p=0.0265 for CXCL10; middle panel figure 3C and D). In 
addition, these patients had elevated biomarker levels over the entire first year (figure 3C, D 
and E; right panel 3C&D shows total area under curve of first year). In contrast to the 
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To assess the predictive value of the biomarkers for flares after the first year, we analysed 4 
patients of whom longitudinal samples were available within 7 months before a flare (Figure 
3F and supplementary figure 2). In patients #1 and #2, a raise of the levels of galectin-9 and 
CXCL10 (even while below cutoff) was observed from up to 7 months prior to flare, with 
levels above the cutoff up to 6 months prior for galectin 9 and up to 3 months prior for 
CXCL10. These biomarker fluctuations were observed even before clinical symptoms of a 
flare became apparent. In patients #3 and #4, persistently borderline cutoff values were 
observed for galectin-9 and CXCL10 in the 12 months prior to flare and biomarkers were 
elevated above the cutoff during flare. In contrast, CK did not increase prior to and during 
flare in patient #4, and did not demonstrate an increase until flare in patient #2 and #3. Only 
in patient #1 CK steadily increased by 3 months prior to flare. It was also observed that 
galectin-9 and CXCL10 stayed high during continued disease activity on medication after the 
start of flare, while in 3 out of 4 individuals CK decreased to within normal limits by the first 
timepoint following start of clinical flare despite continued disease activity. 
 
In conclusion, persistently high or rising galectin-9 and CXCL10 levels above their cut-off 
values may be indicative of ongoing (sub)clinical inflammation or an imminent flare, even 
with a lack of clinical symptoms or elevated CK.  
 
Measurement in dried blood spots 
To facilitate minimally invasive (at-home) biomarker assessment and broad clinical 
applicability with centralization of diagnostic cores, we assessed galectin-9 and CXCL10 
measurement in dried blood spots (DBS) and paired plasma and serum samples. Patient 
characteristics are shown in supplementary table 7. The correlation between the biomarker 
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than for galectin-9 (rs=0.62/0.58 (plasma/serum); figure 4A and B). Galectin-9 and CXCL10 
levels were similar in plasma and serum (figure 4C). Both galectin-9 and CXCL10, as 
measured in DBS, were capable of discriminating between active JDM patients and healthy 
controls (p=0.0040 and p<0.0001, respectively; figure 4D), the latter having similar 
biomarker levels to JDM patients in remission (figure 2). In conclusion, both galectin-9 and 
CXCL10 are suited to be measured in dried blood spots as biomarkers for JDM. 
 
DISCUSSION 
In this study galectin-9 and CXCL10 were validated as strong, reliable and sensitive 
biomarkers for disease activity in JDM, and both identified as promising biomarkers for adult 
patients with (dermato)myositis. Galectin-9 and CXCL10 strongly distinguished between 
JDM patients with active disease and patients in remission, even under immunosuppressive 
treatment. Furthermore, we show that Galectin-9 and CXCL10 are relatively specific for 
auto-inflammatory myopathies in adult and paediatric patients, as they were not as highly 
increased or did not differentiate between active disease and remission in other autoimmune 
diseases, like LoS and SLE. Both cross-sectionally and longitudinally, galectin-9 and 
CXCL10 outperformed CK, which is commonly used as a laboratory marker for disease 
activity and is one of the current criteria for determining clinically inactive disease in JDM. 
(39,47) Continuously elevated or rising biomarker levels, as determined in a prospective 
patient cohort, may be indicative of an imminent disease flare up to several months before 
clinical symptoms, even in absence of elevated CK. The biomarkers may therefore be 
promising to use in longitudinal follow-up of patients for monitoring of disease activity. 
Lastly, galectin-9 and CXCL10 can be reliably measured in plasma, serum and minimally 
invasive DBS. It has recently been shown that capillary concentrations of CXCL10 correlate 
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moderate correlation for circulating levels of galectin-9 and levels in DBS could either result 
from liberation of intracellularly stored galectin-9 and/or release from its carrier proteins 
upon elution and dilution. 
 
Strengths and limitations of this study 
This study has several strengths. Although many biomarkers are being identified for a variety 
of diseases, only few are implemented into clinical practice due to a lack of reproducibility 
and diagnostic accuracy. Galectin-9 and CXCL10 however have a high discriminative power 
and strong, reproducible correlation with disease activity. Thanks to a large international 
collaborative effort we have been able to extensively validate galectin-9 and CXCL10 in a 
large number of patients with JDM from three independent cross-sectional cohorts, despite 
the rarity of the disease. The additional analyses in a prospective JDM cohort with a long 
follow-up time add important information on the value of galectin-9 and CXCL10 in clinical 
follow-up. Next to the clinical validation in this study, the biomarkers have undergone a 
technical validation at the diagnostic department of the UMC Utrecht, which has 
demonstrated the stability of the biomarkers and reproducibility of the measurements. In 
addition, we have explored a minimally invasive diagnostic method of measuring the 
biomarkers in dried blood spots. 
The findings of this study need to be interpreted keeping in mind the observational nature of 
the data and the use of a combination of clinical scores and CK (PRINTO criteria for 
clinically inactive disease) as gold standard for disease activity. (39,47) Importantly, galectin-
9 and CXCL10 can complement, but not replace clinical assessment by experienced health 
care professionals. However, both biomarkers outperform the currently used marker CK, 
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Comparison with other studies 
A recent study using the SOMAscan assay also identified both galectin-9 and CXCL10 
among the top upregulated proteins in JDM, correlating with disease activity assessed by 
PGA. (49) CXCL10 was previously shown to correlate with disease activity in JDM, (26,30–
32,50) and is well known as an interferon-inducible chemokine that can be elevated in other 
types of myositis and autoimmune diseases. (29,33) In our study galectin-9 was a specific 
biomarker for inflammatory myopathies. In JDM patients, high circulating interferon-alpha 
levels have been found and in one group of JDM patients, more than 75% of patients had a 
positive interferon signature. (51,52) Circulating galectin-9 and CXCL10 could therefore be a 
direct reflection of active interferon-driven inflammation, which is supported by a recent 
study describing galectin-9 as a marker for the IFN signature in SLE and antiphospholipid 
syndrome. (53) Since the biomarkers correlate with disease activity in tissues, local tissue 
cells are the main candidate producers of the proteins. Indeed, galectin-9 cannot only be 
detected in the circulation, but also locally within inflamed muscle and skin, where it is 
mainly present in activated tissue macrophages and capillary endothelial cells (data not 
shown). A similar expression pattern, in tissue mononuclear cells and endothelial cells, was 
previously demonstrated for CXCL10. (54,55) Local biomarker production within inflamed 
tissues fits our previous observation that the biomarker levels only slowly decline after stem 
cell transplantation, as tissue infiltrating immune cells (and endothelial cells) are likely less 
affected by immune ablative pre-conditioning than circulating immune cells. (27)    
 
Implications for clinical practice 
Implementation of galectin-9 and CXCL10 into clinical practice, as tools to monitor disease 
activity and guide treatment, might enable personalized treatment strategies for patients with 
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that diagnostic centres can decide to use their biomarker of choice depending on availability 
and feasibility. Biomarker levels below the set cut-off reflect the absence of disease activity, 
which could allow tapering of immunosuppressive medication. Rising or persistently high 
levels might be indicative of an insufficient response to therapy and/or an imminent flare, 
even in the absence of clinical symptoms or elevated CK, possibly reflecting subclinical 
inflammation. Elevated biomarker levels might therefore indicate the need for intensification 
of treatment or slower tapering of steroids. With this envisioned personalized treatment 
strategy we respond to important patient-reported needs: a recently conducted patient survey 
by CureJM, the American patient organisation for juvenile myositis, has shown that 
“predictors for disease flares” and “new treatments, less side effects” are two of the top-three 
research priorities chosen by patients. (56) Galectin-9 and CXCL10 may also provide an 
objective outcome measure for response to therapy in future clinical trials assessing novel 
therapeutics. Our study has shown that galectin-9 and CXCL10 levels in DBS correlate with 
venous levels and can differentiate active JDM patients from healthy controls. Longitudinal 
assessment of these biomarkers via DBS, which requires further study, has potential for high 
utility in the future, as DBS can be sampled at home by simple capillary finger-prick. Since 
protein levels remain remarkably stable over time in DBS, even at room temperature, (57,58) 
they can be sent to a diagnostic centre through regular mail. This enables at-home diagnostics 
and centralization of diagnostic cores for both clinical care and multicentre studies. It also 
ensures maximum accessibility of the biomarker measurements for non-expert medical 
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Unanswered questions and future research 
Galectin-9 and CXCL10 could add important information in the complex differential 
diagnosis of muscle complaints during follow-up, and might aid to discriminate between 
steroid-induced myopathy, non-inflammatory muscle pain and muscle inflammation, all of 
which require different treatment strategies. Especially in these complicated cases, 
biomarkers may also abrogate the need for invasive diagnostic muscle biopsies or costly MRI 
scans, which can sometimes require sedation in young children. This specific potential will 
have to be further investigated in additional prospective studies. Additional prospective 
studies will also have to point out whether 1) one biomarker may be superior in answering 
specific clinical questions concerning JDM, 2) the biomarkers are able to detect mild disease 
activity, 3) the biomarkers also have prognostic value in adult patients with myositis and 4) 
biomarker-guided disease management will improve outcomes of patients with JDM.  
 
Conclusion 
Galectin-9 and CXCL10 were identified and extensively validated as strong, reliable and 
sensitive biomarkers for disease activity in JDM. The biomarkers might facilitate 
personalized treatment strategies for patients with JDM, by providing a diagnostic monitoring 
tool to guide treatment.  
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FIGURE AND TABLE LEGENDS 
Table 1. Overview of JDM cohorts 
Overview of the different JDM cohorts and analyses. HC = adult healthy control; JDM = 
juvenile dermatomyositis; DM = adult dermatomyositis; NSM = adult non-specific/overlap 
myositis; SMA = spinal muscular atrophy; EF = adult eosinophilic fasciitis; LoS = localized 
scleroderma; SLE = systemic lupus erythematosus; NL = Netherlands, Sing = Singapore; 
EVC = external validation cohort; IVC = internal validation cohort; DBS = Dried blood 
spots. 
 
Table 2. Sensitivity and negative predictive value of determined cut-off values for 
galectin-9 and CXCL10 in internal validation cohort.  
Cut-off values for galectin-9 and CXCL10 were determined based on the maximal Youden’s 
index with a sensitivity higher than 0.80, to ensure a low risk of ongoing active inflammation 
with a biomarker value below the set cut-off. Only 1 sample per patient per category (‘active’ 
or ‘remission’) was included in the analysis (i.e. cohort ‘JDM NL’ as shown in figure 2 and 
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Figure 1. Cross-sectional validation of galectin-9 and CXCL10 as biomarkers for 
disease activity in JDM in two independent validation cohorts. 
(A&B) Galectin-9 and CXCL10 levels were measured in serum samples from JDM patients 
by multiplex immunoassay. Patients were stratified into four groups based on disease activity 
and use of medication: active disease before start of treatment (“A”), active disease on 
medication (“AM”), remission on medication (“RM”) and remission off medication (“R”). 
Medians and interquartile ranges are shown, on a log scale. Kruskall-Wallis with Dunnett’s 
post hoc test for multiple comparisons; multiplicity adjusted P values are reported. P values 
>0.999 are not shown. (A) External validation cohort (EVC) (A: n=12; AM: n=27, RM: 
n=28, R: n=12). (B) Internal validation cohort (IVC) (A: n=25; AM: n=30, RM: n=16, R: 
n=12). Of note: In the AM group, for 1 patient 3 samples (from different time points at least 3 
months apart) were included and for 6 patients 2 samples (also from different time points, 2 
to 11 months apart) were included. Exclusion of these extra samples did not change the 
statistical significance between the groups (data not shown). (C&D) Galectin-9 and CXCL10 
levels in paired patient samples during active disease and remission (regardless of treatment) 
from EVC (C, n=8) and IVC (D, n=13). The median time between the two samples was 23 
months in the EVC and 12 months in the IVC. Wilcoxon matched-pairs signed rank test. 
(E&F) ROC curves of galectin-9, CXCL10, and CK in the EVC (E) and IVC (F), regardless 
of medication. Only patients with a complete dataset for the specific ROC curve were 
included in the analysis. Statistic details of the ROC curve analysis are shown in 
supplementary table 3. (G&H) Correlation of galectin-9 and CXCL10 with CMAS in EVC 
(G, n=79) and IVC (H, n=61). Spearman rank correlation. Biomarkers are shown on a log 
scale. A = active pre-treatment; AM = active on medication; RM = remission on medication; 
R = remission off medication; CMAS = childhood myositis assessment scale; rs= Spearman 
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Figure 2. The biomarker potential of galectin-9 and CXCL10 in adult inflammatory 
myopathies and systemic autoimmune diseases with skin involvement 
(A) Galectin-9 and (B) CXCL10 were measured in serum samples from patients with JDM 
(Dutch and Singaporean validation cohorts), adult patients with DM, NSM and EF, adult 
healthy controls, and a mixed cohort of adult and juvenile patients with SMA. Where 
applicable, patients were stratified into two groups based on disease activity, regardless of 
their treatment status. Only one sample per patient per activity group was included in the 
analysis; therefore the patient numbers of the internal validation cohort (here “JDM NL”) 
differ from figure 1. Medians and interquartile ranges are shown, on a log scale. (C) 
Galectin-9 and (D) CXCL10 were measured in serum samples from juvenile patients with 
JDM (Dutch cohort) and LoS, adult healthy controls, and a mixed cohort of juvenile and 
adult patients with SLE. Patients were stratified into two groups based on disease activity, 
regardless of treatment status. Only one sample per patient per activity group was included in 
the analysis. Medians and interquartile ranges are shown, on a log scale. (A-D) Statistics for 
comparison between active disease and remission within diseases are shown in regular text 
(upper p value): 2-Way ANOVA with Šídák’s post hoc test for multiple comparisons. 
Statistics for comparison of each disease group with HC are shown in italic text (bottom p 
value): Kruskall-Wallis with Dunnett’s post hoc test for multiple comparisons. Multiplicity 
adjusted P values are reported. P values >0.999 are not shown. A = active disease regardless 
of treatment; R = remission regardless of treatment; HC = adult healthy control; JDM = 
juvenile dermatomyositis; DM = adult dermatomyositis; NSM = adult non-specific/overlap 
myositis; SMA = adult + juvenile spinal muscular atrophy; EF = adult eosinophilic fasciitis; 
LoS = juvenile localized scleroderma; SLE = adult + juvenile systemic lupus erythematosus; 
NL = Netherlands, Sing = Singapore. Patient characteristics are shown in supplementary 
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Figure 3. Galectin-9 and CXCL10 in longitudinal follow-up of patients 
Galectin-9 and CXCL10 were measured in longitudinal samples from JDM patients in a 
prospective cohort. (A&B) Dynamics of galectin-9 and CXCL10 up to 6 years after diagnosis 
of 15 patients without flares, with a first sample taken max. 6 months after start of treatment. 
Both patients with and without intensification of therapy within the first 3 months were 
included. Grey shading indicates the previously determined cut-off values for galectin-9 and 
CXCL10 (19396 pg/mL and 805 pg/mL, respectively). Each datapoint contains between 3 
and 13 samples, which were pooled over the time span around the data point. The median 
interval between two samples from a patient was 3.6 months. Per patient, 4-14 samples were 
included in the analysis (median of 9 samples per patient). Means and standard deviations are 
shown, on a linear scale. (C&D) Galectin-9 and CXCL10 in longitudinal samples from JDM 
patients with a flare within the first year (n=6), after the first year (n=7) or without flares 
(n=15, same patients as figures A&B). Only patients with a first sample taken max. 6 months 
after start of treatment were included. Left panel: longitudinal data within the first year, 
means and standard deviation. Grey shading indicates the previously determined cut-off 
values for galectin-9 and CXCL10 (19396 pg/mL and 805 pg/mL). 2-Way ANOVA with 
Tukey’s post hoc test for multiple comparisons. Multiplicity adjusted P values are reported: P 
values in regular text: flare <12 months versus no flare; P values in italic text: flare <12 
months versus flare >12 months; P values >0.999 are not shown. Middle panel: Galectin-9 
and CXCL10 levels at diagnosis before start of treatment, medians and interquartile ranges, 
2-way ANOVA with Tukey’s post hoc test corrected for all time points measured in left 
panel; Right panel: Total area under the curve (AUC) for each of the three groups in the 
graph shown in the left panel, calculated by the trapezoidal method. 1-way ANOVA with 
Tukey’s post hoc test. Means and 95% CI are shown. (E) Galectin-9, CXCL10 and CK in the 
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the previously determined cut-off values for galectin-9 and CXCL10 and the standard cut-off 
of 150 IU/L for CK. (F) Longitudinal measurement of galectin-9, CXCL10 and CK in an 
individual with a disease flare after the first year. Dotted lines indicate the previously 
determined cut-off values for galectin-9 and CXCL10 (19396 pg/mL and 805 pg/mL, 
respectively). Grey shading indicates the cut-off for CK (150 IU/L). Biomarkers are shown 
on a log scale; time is in months. <12m = patients with a flare in the first year, >12m = 
patients with a flare after the first year; AUC = are under the curve, CK = creatine kinase, 
IU = international units, Dx = diagnosis, CMAS = childhood myositis assessment scale, PGA 
= physician’s global assessment, CAT = cutaneous assessment tool, Pred = prednisone 
(mg/kg/day), MTX = methotrexate (mg/m2/week). Patient characteristics are shown in 
supplementary table 6.  
 
Figure 4. Galectin-9 and CXCL10 measured in dried blood spots and paired plasma 
and serum samples. 
Galectin-9 and CXCL10 levels in dried blood spots (DBS) were compared to levels in paired 
plasma and serum samples from both active JDM patients (n=10) and healthy controls 
(n=12). (A) Spearman correlation between biomarker levels in plasma and DBS, double log 
scale. (B)  Spearman correlation between biomarker levels in serum and DBS, double log 
scale. (C) Paired representation of the biomarker levels in plasma, serum and DBS. Grey 
lines represent healthy controls, black lines represent active JDM patients, and dotted lines 
represent active JDM patients on medication. Biomarkers are shown on a log scale. (D) 
Biomarker levels in DBS compared between HC and active JDM. Mann-Whitney U test. 
Biomarkers are shown on a log scale. HC = healthy control, JDM A = Active JDM patients 
pre-treatment, JDM AM = Active JDM patients on medication. Patient characteristics are 
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Table 1. Overview of JDM cohorts 
  Cohort Abbreviation City, Country Table no Figure no Patients Samples 















Fig 1 & 
S1 








Fig 1 & 
S1 
47 83 26 
Serum 
Adult DM & 
NSM, adult 





JDM NL Suppl 4 Fig 2 47 58 11 
Asian cohort JDM Sing Singapore Suppl 4 Fig 2 12 13   Serum 






















Fig 3 & 
S2 
28 286 
  Serum 
Paediatric HC 5 






Suppl 7 Fig 4 7 10 
  Serum 
Adult HC 4   Plasma 
  DBS 
 EVC = external validation cohort; IVC = internal validation cohort; DBS = dried blood spots; HC = adult healthy control; JDM = juvenile 
dermatomyositis; DM = adult dermatomyositis; NSM = adult non-specific/overlap myositis; SMA = spinal muscular atrophy; EF = adult 
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Table 2. Sensitivity and negative predictive value of determined cut-off values for 
galectin-9 and CXCL10 in internal validation cohort. 
 
Biomarker Cutoff value Sensitivity Specificity NPV PPV 
Galectin-9 19396 pg/mL 0.839 0.923 0.828 0.929 
CXCL10 805 pg/mL 0.871 1.000 0.867 1.000 
Cut-off values for galectin-9 and CXCL10 were determined based on the maximal Youden’s 
index with a sensitivity higher than 0.80, to ensure a low risk of ongoing active inflammation 
with a biomarker value below the set cut-off. Only 1 sample per patient per category (‘active’ 
or ‘remission’) was included in the analysis (i.e. cohort ‘JDM NL’ as shown in figure 2 and 
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